In the PEACE-1 phase 3 study, men with de novo metastatic castration-sensitive prostate cancer (mCSPC) had increased overall survival (OS) with the addition of abiraterone acetate plus prednisone (AAP) to androgen deprivation therapy (ADT) with or without docetaxel (D). In mCSPC males treated with ADT with D or AAP, the 8-month PSA reduction to undetectable levels had been linked to enhanced OS and radiological progression-free survival (rPFS). In males with mCSPC who were receiving treatment in PEACE-1 with the triplet systemic association: ADT+D+AAP, researchers evaluated the relationship between the 8-month PSA value and rPFS and OS.

The research was based on data from 1,172 males who received ADT+/- D +/- AAP. A PSA was necessary for the analysis 8 months after the start of ADT. Data was terminated on June 1, 2021. Both rPFS and OS were evaluated on a global and per-randomization basis. The analysis was done using the 0.2 and 4 ng/ml 8-month PSA cut-offs. Using the Kaplan Meier technique, the median values of rPFS and OS were determined from 8 months of PSA.

In 931 males (79%), PSA levels at 8 months following the start of ADT were available. In 62% of cases, the standard of therapy was ADT + D, and in 56% of cases, the illness was “high volume.” (95% CI [4.3-4.5]) The median follow-up was 4.4 years.

8-month In males with mCSPC in PEACE-1, PSA value highly predicts both rPFS and OS. Therefore, early treatment for males with unfavorable Investigation of 8-month PSA results is required.